View On Demand

A Fast-Tracked, Orphan Drug For Heart Disease

About the Event

Most people haven’t heard of HIT (Heparin-Induced Thrombocytopenia), but as a side effect of one of the most common treatments for heart disease it affects as many as 300,000 people per year.

Heparin is used 12 to 15 million times per year in the US alone during cardiovascular procedures as a post-surgical anticoagulant. HIT is an allergic reaction that causes platelets to clot, which can result in stroke, amputation, and death. Importantly, it can take up to 7 days to establish a diagnosis of HIT, so physicians must treat those suspected of having the diseases while awaiting confirmation. 

Veralox’s lead program VLX-1005 targets the root cause of HIT. In Phase 1 clinical trials, VLX-1005 saw no treatment-based discontinuations, no dose limiting toxicities, and no drug interactions between it and the current standard of care. VLX-1005 has received orphan drug and fast-track designation from the FDA and has begun Phase 2 clinical sites that include Stanford and Yale. Conservative estimates suggest that the market potential for HIT alone is between $850M and $1B.

Join our webinar with Veralox CEO, Jonathan Mow to hear the full story and hear why Hatteras Venture Partners, Genesys Capital, Sanofi Ventures, JDRF T1D Fund, and others have all backed the company.

View On Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.